Contact info

Dr V�ronique Michaud
CRCHUM � Pavillon R
900, Saint-Denis � Room R08.480
Montreal, QC H2X 0A9

Tel: 1-514-890-8000, ext. 15812
E-mail: [email protected]

Research keywords

Mrs V�ronique Michaud is assistant professor at the Faculty of Pharmacy, University of Montreal and researcher at the CRCHUM (Research center of Centre Hospitalier de l'Universit� de Montr�al). She received her Bachelor degree in Pharmacy in 2001 from Laval University in Quebec City followed by a MSc degree and a PhD degree in drug metabolism from the University of Montreal in 2003 and 2009, respectively. She has completed post-doctoral studies in the department of McGill AIDS Centre at the Lady Davis Institute, McGill University, Montreal, under the supervision of Dr Mark Wainberg in 2009-2010. She undertook a second post-doctoral training in the department of Clinical Pharmacology at the School of medicine, Indiana University, Indianapolis, with Dr David Flockhart.

Research interests of Dr Michaud have been directed towards the study of factors responsible for intersubject variability in drug response. More specifically, she has developed expertise in the role of drug metabolism by the cytochromes P450 superfamily as a factor to explain variability in drug action. Among her topics of interest are the pharmacogenetics and the study of intracellular drug-metabolism leading to modulation of drug action or side-effects. Dr Michaud has integrated in her research mechanistic approaches and models (in vitro drug metabolism, molecular biology, cell culture) as well as designed and performed studies in healthy volunteers and patients (pharmacokinetics, pharmacodynamics). She has published more than 19 referred articles and more than 75 published abstracts at national and international meetings. She has received previously numerous awards including a MDS Pharma Services scholarship for her master studies. During her training, she received a CIHR studenship and a CIHR fellowship. Indeed, her CIHR fellowship application was ranked first overall, which earned her the Bisby award. Dr Michaud has also received the AFPC Future Academic Leader Award and her thesis has been ranked in the in the top 5% of thesis presented at University of Montreal. She is a member of numerous societies. She is now applying research activities to the treatment of disease of special type 2 diabetes patient subpopulation.

Click here for pdf CV

Click here for PubMed listing

To better understand intersubject variability in drug action. My research interests are to evaluate the contribution of major system involved in drug elimination i.e., CYP450 drug-metabolizing enzymes with a particular attention to the role of disease state. Another important factor taken into consideration throughout my projects is the determination of drug concentrations not only in plasma but more specifically in tissues, i.e., at the vicinity of drug effector sites. The distinctive aspects of my research program relate: 1) to the study of the role of extra-hepatic drug metabolism by CYP450, 2) to the study of influence of diseases such as diabetes on metabolic capacity and drug transport, 3) pharmacokinetic and pharmacogenetic studies to characterize mechanisms underlying inter-individual variability in drug response (desired and/or undesired effects), 4) drug-drug interaction studies with a special attention to cardiovascular, antidiabetic and antiretroviral drugs. The knowledge generated will contribute to reducing drug inefficacy and toxicities by better adjusting drug dose or selecting more appropriate drugs.

Projects

• Effects of Type 2 Diabetes (T2D) on drug disposition and CYP450 activities; a special look at extra-hepatic metabolism (PI; CIHR)
• Evaluation of the impact of T2D on intestinal CYP450s in humans (PI; CIHR)
• The first characterization of functional CYP450 activities in human cardiac myocytes: Modulation of cardiac potassium channel block due to local metabolism of QT-prolonging drugs (Co-PI; CIHR & Heart and Stoke Foundation of Canada)
• �valuation des d�sordres musculaires induits par les statines; r�le des transporteurs membranaires MCT1 et MCT4
• Pharmacokinetics of Antiplatelet Drugs in Type 2 Diabetes Patients; the PANDDA study (Pilot grant, MDRC)